SecBot SecBot

RPRX drug pipeline

Royalty Pharma plc · 3 rated drugs
$69.31
+0.5% 1-day · Nov 13
Next catalyst
Nov 27, 2026
neladalkib PDUFA date · in 11 days
Typical move on FDA news
±1.8%
1-day, median of 6 events
IV rank
No data
No current options data
Rated drugs
3
3 neutral
Phase 3 trials
0
0 with results posted

Upcoming catalysts

3 dated
  1. Nov 27, 202611d
    neladalkib
    PDUFA date · non-small cell lung cancer
  2. Apr 23, 2027158d
    deucrictibant
    PDUFA date · hereditary angioedema attacks
  3. May 27, 2027192d
    obexelimab
    PDUFA date · immunoglobulin G4-related disease (IgG4-RD)

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed. FDA approval was August 6, 2024; EMA approval was September 17, 2025.

Voranigo vorasidenib Updated Nov 5

What to watch

Voranigo has no pending binary catalyst. Investors should track Servier's commercial execution and quarterly royalty receipts reported by RPRX. RPRX's next major catalyst is the November 27, 2026 PDUFA for neladalkib (a different drug), which is unrelated to Voranigo. Voranigo's contribution to RPRX's value will unfold gradually through sales growth and market expansion across its approved territories.

Bull case
  • First and only FDA-approved targeted therapy for Grade 2 IDH-mutant glioma, addressing a clear unmet need with no direct competition.
  • Phase 3 INDIGO data showed compelling efficacy (median PFS 27.7 months vs. 11.1 months for placebo), and extended follow-up at ASCO 2026 showed median PFS of 44.1 months, reinforcing durable benefit.
  • Royalty Pharma projects peak annual sales above $1 billion, which would generate over $150 million in annual royalty revenue for RPRX at the 15% rate.
Bear case
  • Royalty Pharma is not the developer or marketer of Voranigo; it only holds a royalty interest. It has no control over Servier's pricing, commercialization, or manufacturing.
  • The addressable patient population is narrow (Grade 2 IDH-mutant glioma), which may limit peak sales potential despite high per-patient pricing.
  • NICE draft guidance in the UK (March 2026) recommends Voranigo for NHS use, but reimbursement negotiations and market access in Europe could affect the pace of uptake.
● neutral
Impact
PhasePhase 3
Time to marketThe Phase 3 primary completion date is estimated around December 2027, with study completion around April 2028. If results are positive, an FDA submission would follow, putting a potential approval decision no earlier than late 2028 or 2029.

cliramitug Updated Nov 5

What to watch

Cliramitug has no near-term catalyst for RPRX. The next meaningful event is the Phase 3 DepleTTR-CM topline readout, estimated around December 2027. RPRX investors should focus on nearer-term drivers: the November 27, 2026 PDUFA for neladalkib (a separate royalty asset) and the company's Q4 earnings. Cliramitug is a long-term call option within RPRX's portfolio, not a near-term trading catalyst.

Bull case
  • Cliramitug targets a novel mechanism (amyloid depletion) that could differentiate it from existing stabilizers like Pfizer's tafamidis and BridgeBio's Attruby, which only prevent new amyloid formation.
  • Phase 1/2 data published in NEJM and Nature Medicine showed no drug-related serious adverse events and dose-dependent reductions in cardiac amyloid burden, supporting the therapeutic hypothesis.
  • AstraZeneca has guided peak sales potential of $3-5 billion for cliramitug, and the ATTR-CM market is projected to grow rapidly (estimates range from $17B in 2026 to $45B+ by 2030).
Bear case
  • The Phase 3 DepleTTR-CM trial is event-driven (mortality and cardiovascular events) and may take years to read out; primary completion is not expected until at least December 2027.
  • Pfizer's tafamidis franchise generated ~$6.3B in 2025 and is deeply entrenched, with patent protection extended to 2031 via settlements. BridgeBio's Attruby and Alnylam's therapy are also competing in the space.
  • Royalty Pharma's 3-4% royalty is a thin slice of any future sales. Even at $3-5B in peak sales, the annual royalty would be $90-200M, modest relative to RPRX's ~$3.5B annual portfolio receipts.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2004. No further regulatory milestones for the originator product.

Tysabri natalizumab Updated Nov 5

What to watch

Tysabri has no upcoming binary catalysts; it is a mature product in gradual biosimilar-driven decline. For Royalty Pharma, the key question is how quickly Tysabri royalties erode versus growth in the rest of the portfolio. Watch Biogen's quarterly Tysabri sales reports for the pace of market share loss to Tyruko, and monitor Royalty Pharma's portfolio receipts disclosures for the Tysabri royalty trend. Royalty Pharma's next portfolio-wide catalyst is the PDUFA date for neladalkib on November 27, 2026, a separate drug entirely.

Bull case
  • Tysabri remains a significant revenue generator for Biogen with $1.665 billion in global sales in 2025, and Royalty Pharma collects a royalty on those sales (reportedly 18% up to $2 billion and 25% above that threshold).
  • Royalty Pharma acquired the Tysabri royalty stream in 2017 for up to $2.85 billion, and the drug has continued to generate substantial royalty income for years since, demonstrating the durability of the royalty model.
  • Tysabri's decline has been gradual (only 2.9% revenue decline in 2025 despite biosimilar competition in Europe), suggesting the brand retains meaningful market share and patient loyalty.
Bear case
  • Tysabri faces direct biosimilar competition from Tyruko (Sandoz/Novartis), which launched in Europe in 2023 and the US in November 2025, putting sustained downward pressure on sales and royalties.
  • Royalty Pharma itself stated in its Q1 2026 pre-quarterly communication that it expects Royalty Receipts from Tysabri to decline in 2026 due to biosimilar competition.
  • Tysabri carries a boxed warning for progressive multifocal leukoencephalopathy (PML), a rare but often fatal brain infection, which limits its addressable patient population and creates ongoing safety liability.

Other drugs in filings and trials

no drug report yet
  • neladalkib Next: PDUFA date · Nov 27, 2026 Last: NDA filed · May 1, 2026
  • deucrictibant Next: PDUFA date · Apr 23, 2027 Last: NDA filed · Jul 31, 2026
  • obexelimab Next: PDUFA date · May 27, 2027 Last: BLA filed · Aug 31, 2026
  • ecopipam Last: NDA filed · Aug 31, 2026
  • Ziihera Last: PDUFA decision · Aug 25, 2026

Past FDA events & how the stock moved

6 events
DateDrugEvent1 day5 days
Aug 31, 2026obexelimabBLA filed+2.4%−0.4%
Aug 31, 2026ecopipamNDA filed+2.4%−0.4%
Aug 25, 2026ZiiheraPDUFA decision+0.8%+1.6%
Jul 31, 2026deucrictibantNDA filed−3.1%−3.8%
May 1, 2026neladalkibNDA filed+0.2%+1.4%
Apr 1, 2026neladalkibNDA filed+1.3%+0.7%